ATE554750T1 - Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen - Google Patents
Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungenInfo
- Publication number
- ATE554750T1 ATE554750T1 AT98908884T AT98908884T ATE554750T1 AT E554750 T1 ATE554750 T1 AT E554750T1 AT 98908884 T AT98908884 T AT 98908884T AT 98908884 T AT98908884 T AT 98908884T AT E554750 T1 ATE554750 T1 AT E554750T1
- Authority
- AT
- Austria
- Prior art keywords
- hydrophobic pharmaceutical
- formulations
- active ingredients
- pharmaceutical active
- preparations containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3987097P | 1997-03-05 | 1997-03-05 | |
US4125197P | 1997-03-18 | 1997-03-18 | |
PCT/US1998/004134 WO1998038984A2 (en) | 1997-03-05 | 1998-03-04 | Formulations for hydrophobic pharmaceutical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE554750T1 true ATE554750T1 (de) | 2012-05-15 |
Family
ID=26716539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98908884T ATE554750T1 (de) | 1997-03-05 | 1998-03-04 | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen |
Country Status (11)
Country | Link |
---|---|
US (2) | US6248771B1 (de) |
EP (1) | EP1014953B1 (de) |
JP (1) | JP4713698B2 (de) |
AT (1) | ATE554750T1 (de) |
AU (1) | AU743024B2 (de) |
CA (1) | CA2282439C (de) |
CO (1) | CO4940469A1 (de) |
ES (1) | ES2384551T3 (de) |
HK (1) | HK1028548A1 (de) |
NZ (1) | NZ510991A (de) |
WO (1) | WO1998038984A2 (de) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846839B1 (en) | 1995-06-07 | 2005-01-25 | Sugen, Inc. | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US6395734B1 (en) | 1998-05-29 | 2002-05-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7064114B2 (en) | 1999-03-19 | 2006-06-20 | Parker Hughes Institute | Gel-microemulsion formulations |
AU3630100A (en) * | 1999-03-19 | 2000-10-09 | Parker Hughes Institute | Quinazoline formulations and therapeutic use thereof |
CA2365945A1 (en) * | 1999-04-09 | 2000-10-19 | Max-Planck-Institute For Biochemistry | Products and methods for treating ptp lar related diseases |
KR20020029419A (ko) | 1999-07-07 | 2002-04-18 | 다비드 에 질레스 | 퀴나졸린 유도체 |
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
EP1259234B9 (de) * | 1999-12-30 | 2007-02-14 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie |
DE60112268T2 (de) | 2000-03-06 | 2006-05-24 | Astrazeneca Ab | Verwendung von quinazolinderivate als inhibitoren der angiogenese |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
CA2410509A1 (en) | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
EP1296973B1 (de) | 2000-06-24 | 2008-11-05 | AstraZeneca AB | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten |
AU2002216758A1 (en) * | 2000-07-03 | 2002-01-14 | Astrazeneca Ab | Quinazolines with therapeutic use |
MXPA03000720A (es) * | 2000-07-24 | 2004-11-01 | Upjohn Co | Sistemas auto-emulsificantes de suministro de medicamentos para medicamentos lipofilicos extremadamente insolubles en agua. |
KR20030024849A (ko) * | 2000-08-10 | 2003-03-26 | 델시스 파머수티컬 코포레이션 | 소수성 약물의 개선된 고형 약제학적 투여 제제 |
US20050158271A1 (en) * | 2000-10-11 | 2005-07-21 | Lee Sang C. | Pharmaceutical applications of hydrotropic polymer micelles |
US20030031715A1 (en) * | 2000-10-11 | 2003-02-13 | Kinam Park | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof |
WO2002069936A2 (en) * | 2001-03-02 | 2002-09-12 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical composition of ibuprofen |
US6912582B2 (en) | 2001-03-30 | 2005-06-28 | Microsoft Corporation | Service routing and web integration in a distributed multi-site user authentication system |
US6599902B2 (en) | 2001-05-30 | 2003-07-29 | Sugen, Inc. | 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
US6720002B2 (en) * | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
US7109185B2 (en) * | 2001-11-21 | 2006-09-19 | Sugen, Inc. | Pharmaceutical formulations comprising indolinone derivatives |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
KR20040085151A (ko) * | 2002-01-17 | 2004-10-07 | 뉴로젠 코포레이션 | 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체 |
CN1308326C (zh) * | 2002-02-15 | 2007-04-04 | 法马西亚和厄普乔恩公司 | 吲哚满酮衍生物的制备方法 |
MY135609A (en) * | 2002-02-26 | 2008-05-30 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
SI1499311T1 (sl) * | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze |
US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
KR20040106391A (ko) | 2002-04-26 | 2004-12-17 | 니뽄 신야쿠 가부시키가이샤 | 퀴나졸린 유도체 및 의약 |
MXPA05006123A (es) * | 2002-12-13 | 2005-09-30 | Neurogen Corp | Analogos de quinazolin-4-ilamina 2-sustituida como moduladores de receptores de capsaicina. |
ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
EP2258365B1 (de) * | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Verwendung von organischen verbindungen zur immunstärkung |
RU2005135329A (ru) | 2003-04-16 | 2006-08-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Замещенные 7-азахиназолины |
JP2006523638A (ja) | 2003-04-16 | 2006-10-19 | エフ.ホフマン−ラ ロシュ アーゲー | キナゾリン化合物 |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
US7329664B2 (en) * | 2003-07-16 | 2008-02-12 | Neurogen Corporation | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues |
GB0317663D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
WO2005026150A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
ATE435015T1 (de) * | 2003-10-16 | 2009-07-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
GEP20084551B (en) | 2004-05-06 | 2008-11-25 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
EP1765810B1 (de) * | 2004-06-08 | 2016-08-17 | Families of Spinal Muscular Atrophy | 2,4-diaminochinazoline zur behandlung spinaler muskelatrophie |
KR100915481B1 (ko) * | 2004-11-09 | 2009-09-03 | 에프. 호프만-라 로슈 아게 | 아미노퀴나졸린 화합물 |
ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
MX2007011250A (es) * | 2005-03-21 | 2007-11-14 | Ivax Pharmaceuticals Sro | Inhibidor de la cristalizacion y su uso en capsulas de gelatina. |
ATE488513T1 (de) | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
US20070287707A1 (en) * | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
AU2007281217B2 (en) | 2006-08-01 | 2013-09-12 | Families Of Spinal Muscular Atrophy | 2,4-Diaminoquinazolines for spinal muscular atrophy |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
WO2008095847A1 (de) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
EP2200613B1 (de) | 2007-09-21 | 2018-09-05 | The Johns Hopkins University | Phenazin-derivate und ihre verwendungen |
WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
EP2257220B1 (de) * | 2008-03-13 | 2017-06-14 | Liebel-Flarsheim Company LLC | Fussbetätigte multifunktionssteuerung für bildgebungssystem |
AU2009247782C1 (en) | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
JP5359333B2 (ja) * | 2009-02-05 | 2013-12-04 | ゼリア新薬工業株式会社 | コロソリン酸含有水性液剤 |
ES2456275T3 (es) * | 2009-02-27 | 2014-04-21 | Ambit Biosciences Corporation | Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos |
PL2473487T3 (pl) | 2009-09-03 | 2017-07-31 | Bristol-Myers Squibb Company | Chinazoliny jako inhibitory kanałów jonowych potasowych |
US9023886B2 (en) * | 2009-11-10 | 2015-05-05 | Celgene Corporation | Nanosuspension of a poorly soluble drug via microfluidization process |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
CN102716103B (zh) * | 2012-07-02 | 2013-12-18 | 西安力邦制药有限公司 | 2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
CN103837615B (zh) * | 2014-02-15 | 2015-05-20 | 青岛农业大学 | 一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法 |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1435821A (en) | 1972-09-26 | 1976-05-19 | Dainippon Toryo Kk | Polymer particles and process for preparing the same |
US3850939A (en) | 1973-02-20 | 1974-11-26 | Parke Davis & Co | 5-nitro-2-thiazolylthiopyridine,1-oxides |
US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
JPS59190967A (ja) * | 1983-04-15 | 1984-10-29 | Hokuriku Seiyaku Co Ltd | 1−(2,6−ジフルオロフエニル)−2−インドリノン誘導体 |
JPS61167616A (ja) * | 1985-01-22 | 1986-07-29 | Adeka Argus Chem Co Ltd | 放射線増感剤 |
EP0448841B1 (de) | 1990-03-19 | 1993-06-02 | Agfa-Gevaert N.V. | Elektronenacceptoren enthaltende Photomaterialien |
AU8641991A (en) | 1990-09-10 | 1992-03-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9501567D0 (en) * | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5763470A (en) * | 1995-06-07 | 1998-06-09 | Sugen Inc. | Benzopyran compounds and methods for their use |
EP0831795A2 (de) * | 1995-06-07 | 1998-04-01 | Sugen, Inc. | Phosphatase inhibitoren |
WO1996040648A1 (en) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
-
1998
- 1998-03-04 CO CO98011791A patent/CO4940469A1/es unknown
- 1998-03-04 WO PCT/US1998/004134 patent/WO1998038984A2/en active IP Right Grant
- 1998-03-04 AT AT98908884T patent/ATE554750T1/de active
- 1998-03-04 JP JP53869898A patent/JP4713698B2/ja not_active Expired - Fee Related
- 1998-03-04 AU AU66806/98A patent/AU743024B2/en not_active Ceased
- 1998-03-04 ES ES98908884T patent/ES2384551T3/es not_active Expired - Lifetime
- 1998-03-04 US US09/034,374 patent/US6248771B1/en not_active Expired - Lifetime
- 1998-03-04 CA CA2282439A patent/CA2282439C/en not_active Expired - Fee Related
- 1998-03-04 NZ NZ510991A patent/NZ510991A/xx not_active IP Right Cessation
- 1998-03-04 EP EP98908884A patent/EP1014953B1/de not_active Expired - Lifetime
-
2000
- 2000-10-28 HK HK00106875.7A patent/HK1028548A1/xx not_active IP Right Cessation
-
2001
- 2001-03-05 US US09/797,842 patent/US6696482B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6696482B2 (en) | 2004-02-24 |
ES2384551T3 (es) | 2012-07-06 |
AU743024B2 (en) | 2002-01-17 |
EP1014953B1 (de) | 2012-04-25 |
EP1014953A2 (de) | 2000-07-05 |
JP4713698B2 (ja) | 2011-06-29 |
US20010012844A1 (en) | 2001-08-09 |
WO1998038984A3 (en) | 1999-01-28 |
WO1998038984A2 (en) | 1998-09-11 |
CA2282439C (en) | 2010-05-04 |
NZ510991A (en) | 2002-11-26 |
CO4940469A1 (es) | 2000-07-24 |
US6248771B1 (en) | 2001-06-19 |
JP2001514626A (ja) | 2001-09-11 |
CA2282439A1 (en) | 1998-09-11 |
AU6680698A (en) | 1998-09-22 |
HK1028548A1 (en) | 2001-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE554750T1 (de) | Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen | |
ATE224717T1 (de) | Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin | |
ES2110377T1 (es) | Formulacion galenica de fenofibrato y aplicacion de la misma. | |
BR9912975A (pt) | Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso | |
ATE216590T1 (de) | Arzneimittelformulierungen für il-12 | |
ATE324907T1 (de) | Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen | |
EP0693924A4 (de) | Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
MY118151A (en) | Pharmaceutical formulations containing voriconazole. | |
ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
PT1033981E (pt) | Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos | |
BR9912694A (pt) | Composto para preparar medicamento de administração pulmonar | |
FI964583A0 (fi) | Tokoferolikoostumuksia biologisesti aktiivisten aineiden antamiseksi | |
ATE270544T1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
FI971776A (fi) | Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi | |
ES2179910T3 (es) | Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
IL136285A0 (en) | Pharmaceutical compositions containing an acid-labile active component | |
BR0012429A (pt) | Fórmulações para il-11 | |
IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
BRPI9916820B8 (pt) | composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método | |
GEP20043377B (en) | Pharmaceutical Complex | |
HUP0004362A2 (hu) | Karbamazepint vagy származékait tartalmazó parenterális készítmények | |
IT1291278B1 (it) | Preparazione farmaceutica a base di nimesulide per uso topico | |
ES2128122T3 (es) | Nuevas formulaciones liquidas. | |
SE9902742D0 (sv) | New pharmaceutical formultion |